ROVAQ Ventures

Founder Christopher Greenwell runs the firm. He is also the principal of The Greenwell Firm, a law practice headquartered at the same Jefferson City, Missouri address. The dual legal-investment structure centralizes all decision-making with Greenwell personally, a model typical of single-principal investment offices in the Midwest. No additional investment committee members or partners have been publicly identified.

The firm sources primarily through the St. Louis innovation ecosystem, co-investing alongside BioGenerator Ventures and the Danforth Technology Company. Greenwell's concurrent legal practice provides a secondary sourcing channel—law firm clients engaged in company formation or intellectual property work can convert to investment opportunities. This proximity to university and research-institution spinouts, particularly from the Donald Danforth Plant Science Center, gives ROVAQ access to deal flow that bypasses traditional venture networks.

Public records treat ROVAQ as a generalist asset manager rather than a registered single-family office or dedicated venture capital firm. Its structure—an investment company run by a lawyer from his law office—does not fit neatly into standard categories. The firm has never registered as an investment adviser and does not appear to raise third-party capital, suggesting it operates as a personal investment vehicle for Greenwell and potentially a small number of close associates.

Based on the single publicly traceable co-investment in Immunophotonics, a clinical-stage biotech company, ROVAQ participates in early-stage to growth-stage rounds. The firm's pattern of co-investing alongside venture builders like BioGenerator suggests a preference for seed and Series A deals, but insufficient portfolio visibility prevents stage-level certainty. The firm has not published an investment thesis or stage mandate.

Confirmed sector exposure includes biotechnology and agricultural technology, driven by the firm's Danforth Center relationships. The Immunophotonics investment adds immuno-oncology to the list. Altss research also tags enterprise software as a potential sector interest, though no specific software portfolio company has been identified in public filings. The firm self-describes as a generalist vehicle, implying additional undisclosed sector activity.